SCHEMBL3829686

SCHEMBL3829686

O=C(CC(O)CN1CCN(CC(=O)NC2CCCCC2)CC1)Nc1ccccc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.54
KDM4E B2RXH2 1/20 0.54
KMT2A Q03164 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CHRNB2 P17787 3/20 0.47
CHRNB4 P30926 3/20 0.47
CHRNA3 P32297 3/20 0.47
CHRNA4 P43681 3/20 0.47
CYP3A4 P08684 1/20 0.46
GAA P10253 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
POLB P06746 1/20 0.46
DRD4 P21917 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3831963 0.99 ALDH1A1 (0.55) ALDH1A1KDM4EKMT2ANPC1RAB9A
SCHEMBL3832557 0.82 MAPT (0.60) ALDH1A1KDM4EKMT2ATSHRHSD17B10
SCHEMBL4857993 0.80 ALDH1A1 (0.54) ALDH1A1TSHRCYP3A4CYP2D6
SCHEMBL3826897 0.80 MEN1 (0.55) ALDH1A1KDM4EKMT2ATSHRHSD17B10
SCHEMBL3833776 0.80 CYP2C19 (0.60) ALDH1A1KDM4EKMT2ANPC1RAB9A
SCHEMBL3831166 0.79 ALDH1A1 (0.53) ALDH1A1KDM4EKMT2ANPC1CYP3A4
SCHEMBL3829146 0.79 MAPT (0.64) ALDH1A1KDM4EKMT2ANPC1RAB9A
SCHEMBL3826668 0.79 CYP3A4 (0.58) ALDH1A1KDM4EKMT2ATSHRHSD17B10
SCHEMBL4857823 0.79 ALDH1A1 (0.55) ALDH1A1KMT2ATSHRCYP3A4CYP2D6
SCHEMBL3826714 0.78 ALDH1A1 (0.54) ALDH1A1KDM4EKMT2ANPC1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578737-B1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS INC (US) 2009-09-16 EP disclosed
US-7566717-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2009-07-28 US disclosed
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS PALLE VENKATA 2008-11-06 US disclosed
US-20070155728-A1 Substituted Heterocyclic Compounds PALLE VENKATA 2007-07-05 US disclosed
US-7205303-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2007-04-17 US disclosed
EP-1578737-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2005-09-28 EP disclosed
US-20040176356-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-09-09 US disclosed
WO-2004063180-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176356-A1 Substituted heterocyclic compounds KCNH1, KCNJ2, SCN5A ALDH1A1 215/4885KDM4E 3425/4885KMT2A 2698/4885
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, SDHA, COQ8A ALDH1A1 281/4885KDM4E 2949/4885KMT2A 3029/4885
US-20070155728-A1 Substituted Heterocyclic Compounds KCNH1, SDHA, COQ8A ALDH1A1 281/4885KDM4E 2949/4885KMT2A 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.